-- First-of-its-kind systematic review on the clinical relevance of test values from the QuantiFERON-TB Gold Plus TB1 and TB2 blood collection tubes has been published

-- Study including 4,050 subjects highlights the value of the TB2 tube and the detection of CD8 T-cell responses for immunocompromised patients, a key risk group for TB disease

-- Higher interferon-gamma production difference between TB2 and TB1 tubes in active TB compared to latent TB subjects suggests stronger CD8 T-cell response

--QIAGEN leverages QuantiFERON®-TB technology to advance global efforts against TB
--TB IGRA testing now accessible in high burden, low resource and decentralized settings
--Study data also showcased at the Union World Conference show promising results

QIAGEN announced that Nigeria has published guidelines recommending QuantiFERON®-TB Gold Plus (QFT®-Plus) in screening for latent TB infection as part of Nigeria’s strategy to prevent the spread of TB.

Germantown, Maryland, and Hilden, Germany, October 5, 2017 – QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of QuantiFERON^®-TB Gold Plus (QFT^®-Plus), the fourth generation of its leading blood test for tuberculosis (TB) infection. QFT-Plus kits will be available on October 9, 2017 for diagnostic use following U.S. Food and Drug Administration approval in June.

The French decision to reimburse interferon-gamma release assays (IGRAs) for TB screening includes QuantiFERON-TB® Gold Plus (QFT-Plus®) and T-SPOT®.TB Test.

NEW YORK, June 8, 2017 – Qiagen said today that its QuantiFeron-TB Gold Plus (QFT-Plus) blood test for detecting latent tuberculosis infection has received US Food and Drug Administration approval.

Qiagen's response to the open letter sent by TAG, TB CAB and India CAB re: Marketing and use of QuantiFERON-TB Gold for active TB in India and high TB burden countries.